Histidine Supplementation for Alzheimer's Disease

Recruiting in Palo Alto (17 mi)

Overseen byWells Reynolds, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Wake Forest University Health Sciences

Prior Safety Data

Trial Summary

What is the purpose of this trial?Oral supplementation of histidine in patients with cognitive dysfunction should increase brain anserine, carnosine and histamine levels which will result in improved cognition via numerous proven in vivo mechanisms including increasing blood flow, neurogenesis, angiogenesis, activation of histaminergic neural pathways and autophagy of beta-amyloid protein, which is pathognomonic for Alzheimer's disease. Randomized into one of 2 arms to receive Histidine or placebo to take for up to 3 months. Baseline evaluation and followup evaluation at 3 months postop.

Eligibility Criteria

This trial is for individuals with Alzheimer's Disease who are interested in testing whether a dietary supplement, l-Histidine, can improve their cognitive function. Participants will be randomly assigned to receive either the Histidine supplement or a placebo for three months.

Inclusion Criteria

Live at home currently

I am 50 years old or older.

Clinical Dementia Score of 3.0 or higher

Exclusion Criteria

Psychiatric

Participant Groups

The study is examining if taking l-Histidine orally can boost brain health and cognition in Alzheimer's patients by increasing certain substances that may help blood flow and brain repair. Patients will take the supplement or placebo over three months with evaluations before and after.

2Treatment groups

Active Control

Placebo Group

Group I: Treatment-HistidineActive Control1 Intervention

Treatment-Histidine

Group II: ControlPlacebo Group1 Intervention

Control